Pioron Tablets 30mg (Pioglitazone Hydrochloride)
Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Korea Pavis Pharmaceutical Co., Ltd.
MFDS item code 201901930 · Approved 2019.03.29
This product's status changed to Expired on 2024.03.29. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to enhance blood sugar control in patients with Type 2 Diabetes. It can be administered alone and may also be used in combination with other antidiabetic agents such as sulfonylureas, metformin, and insulin when there is insufficient effect. Additionally, it is important for diabetes patients to improve their lifestyle habits in conjunction with drug therapy, including dietary management, exercise, and weight loss if necessary. This comprehensive treatment approach significantly aids both initial treatment and the sustained effectiveness of the medication. In conclusion, this drug is effective in improving blood sugar control and is used in the treatment of Type 2 Diabetes.
This medication is administered orally once daily, regardless of meals. Diabetes management should be individualized. Ideally, response to treatment should be assessed by monitoring glycated hemoglobin (HbA1c), which is a more accurate diagnostic measure than fasting blood glucose (FBG). Glycated hemoglobin reflects blood glucose levels over the previous 2 ~ 3 months. Clinically, this medication should be administered for an appropriate period (at least 3 months) to evaluate changes in glycated hemoglobin, provided that glycemic control in the patient with diabetes does not worsen. 1. Monotherapy This medication may be initiated as monotherapy at 15 mg of pioglitazone once daily in patients whose blood glucose is not adequately controlled by diet and exercise. If the initial dose does not provide an adequate effect, the dose may be increased to 30 mg once daily. Combination therapy should be considered for patients who do not respond adequately to monotherapy. 2. Combination therapy 1) Sulfonylureas: This medication may be administered in combination with a sulfonylurea. The initial dose is 15 mg once daily. When used in combination with this medication, the current sulfonylurea may be continued at the same dose and regimen. However, if the patient experiences symptoms of hypoglycemia, the sulfonylurea dose should be reduced. 2) Metformin: This medication may be administered in combination with metformin. The initial dose is 15 mg once daily. When used in combination with this medication, the current metformin may be continued at the same dose and regimen. It is unlikely that the metformin dose will need to be adjusted because of hypoglycemic symptoms during combination therapy with this medication. 3) Insulin: This medication may be administered in combination with insulin at a dose of 15 mg once daily. The current insulin dose may be maintained when combination therapy with this medication is initiated. However, in patients receiving this medication with insulin, the insulin dose may be reduced by 10 ~ 25 % if symptoms of hypoglycemia occur or plasma glucose falls to 100 mg/dL or less. Subsequent dose adjustments should be individualized according to the degree of glycemic control. • Maximum recommended dose For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Dose adjustment is not recommended in patients with renal impairment (see the Renal Impairment subsection under General Precautions). Treatment with this medication must not be initiated if the patient has clinical evidence of active liver disease or elevated serum aminotransferase levels (ALT at least 2.5 times the upper limit of normal) at the start of treatment (see Effects on the Liver under Adverse Reactions and General Precautions). Monitoring of liver enzymes is recommended in all patients before starting treatment and periodically thereafter. No data are available on the use of this medication in combination with other thiazolidinediones.
Children under 18 years of age: Use is not recommended because there is no experience with its use.
This drug is used for the treatment of Type 2 Diabetes and works in conjunction with insulin to regulate blood sugar. When taking this medication, there is a risk of symptoms of heart failure appearing or worsening, so careful observation of symptoms such as weight changes, shortness of breath, and edema is required. It is safer for patients with heart failure or a history of heart failure to avoid using this medication. Additionally, this drug may cause fluid retention, which can result in side effects for patients with heart disease, necessitating caution. Patients with bladder cancer or a history of bladder cancer should not take this medication. Patients with impaired liver function or severe kidney impairment should avoid using this drug, and regular liver or kidney function tests are recommended. Women who are pregnant or may become pregnant should avoid taking this medication, and premenopausal women using this drug should utilize appropriate contraception as the likelihood of becoming pregnant may increase. The risk of hypoglycemia may increase when this medication is used with other antidiabetic agents, so one should be aware of hypoglycemic symptoms and how to manage them. Side effects such as edema, weight gain, headache, upper respiratory infections may occur, and in severe cases, medical consultation is necessary. Drug interactions may occur, so if other medications are being taken, it is essential to inform a doctor or pharmacist. Safety for children and patients under 18 years has not been established, and elderly patients should also use it with caution. In case of overdose, seek appropriate medical treatment immediately. Finally, it is important to store this medication out of the reach of children and to keep it in its original container.
Congestive heart failure, excessive and rapid weight change, difficulty breathing, edema, fluid retention, edema, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, lumbago, dizziness, diarrhea, elevated blood creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular predisposition, worsening of congestive heart failure, emergency room visit due to congestive heart failure, cardiovascular adverse events, dizziness, increased blood glucose, elevated ALT/AST, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, indigestion, nausea, difficulty breathing, itching, chest discomfort, tremors, chills, gastrointestinal disorders, abdominal pain, epigastric discomfort, numbness, muscle rigidity, discomfort in the head, increased liver enzymes, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormalities, arm weakness, proteinuria, increased blood creatinine, anxiety, insomnia, drowsiness, herpes simplex, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, abdominal pain, heart failure, diabetic macular edema accompanied by vision reduction, fatal and non-fatal liver failure, bladder cancer, fracture
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a container that is protected from light and air and kept away from humid areas. The ideal storage temperature is between 15 and 30 degrees Celsius, with 25 degrees being the most favorable.
White round tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Korea Pavis Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 33.06mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Dongwha Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kujoo Pharmaceutical Co., Ltd.

Pioglitazone Hydrochloride 16.53mg
Tablet · Prescription medication
Kyungdong Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.